The clinical significance of autoantibodies in gastrointestinal malignancies: An overview

Expert Opinion on Biological Therapy

Volumn 7, Issue 4, 2007, Pages 493-507

  Saif, Muhammad Wasif ^a   Zalonis, Antonis ^b   Syrigos, Kostas ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Anti carcinoembryonic antigen; Anti p53; Antimucin antibodies; Antinuclear; Gastrointestinal malignancies

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; APOPTOSIS INHIBITOR; AUTOANTIBODY; CANCER TESTES ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL ANTIGEN; CISPLATIN; DOUBLE STRANDED DNA; EPITHELIAL CELL ADHESION MOLECULE; FAS ANTIGEN; FLUOROURACIL; LIVIN; MONOCLONAL ANTIBODY; MUCIN; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN SM; SINGLE STRANDED DNA; SURVIVIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ADJUVANT CHEMOTHERAPY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; AUTOIMMUNITY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG SENSITIVITY; ESOPHAGUS CANCER; GASTROINTESTINAL CARCINOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; LIVER CANCER; METASTASIS; PANCREAS CANCER; PANCREAS TUMOR; REVIEW; STOMACH CANCER; EXPERT WITNESS; GASTROINTESTINAL TUMOR; IMMUNOLOGY; PHYSIOLOGY;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOIMMUNITY; CELL ADHESION MOLECULES; EXPERT TESTIMONY; GASTROINTESTINAL NEOPLASMS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34047181149     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.4.493     Document Type: Review

References (203)

1. BROLL R, DUCHROW M, OEVERMANN E et al.: p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int. J. Colorectal Dis. (2001) 16:22-27. • This paper describes the evaluation of p53 autoantibodies as a preoperative tumor marker and as a prognosis marker in patients with a colorectal cancer.
2. ZHANG JY, CASIANO CA, PENG XX et al.: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. (2003) 12:136-143.
3. SHIMADA H, TAKEDA A, ARIMA M et al.: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer (2000) 89:1677-1683.
4. SALEH J, KREISSLER-HAAG D, MONTENARH M: P53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- or C-terminus of p53. Int. J. Oncol. (2004) 25:1149-1155.
5. TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Impact of circulating p53 autoantibody monitoring after endoscopic resection in mucosal gastric cancer. Endoscopy (2000) 32:740-741.
6. GANSAUGE S, GANSAUGE F, NEGRI G et al.: The role of anti-p53-autoantibodies in pancreatic disorders. Int. J. Pancreatol. (1996) 19:171-178.
7. SHIOTA G, KISHIMOTO Y, SUYAMA A et al.: Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J. Hepatol. (1997) 27:661-668.
8. KONSTADOULAKIS M, SYRIGOS KN, ALBANOPOULOS C et al.: The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J. Clin. Immunol. (1994) 14:310-313. •• Using an enzyme-linked immunoassay, this paper describes the presence of anti-CEA antibodies in the sera of 71 patients with digestive system cancer, 35 patients with various non-malignant disorders, and 28 normal individuals.
9. ALBANOPOULOS K, ARMACOLAS A, KONSTADOULAKIS M et al.: Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am. J. Gastroenterol. (2000) 95:1056-1061.
10. YAGIHASHI A, ASANUMA K, TSUJI N et al.: Detection of anti-livin antibody in gastrointestinal cancer patients. Clin. Chem. (2003) 49:1206-1208.
11. MEGLIORINO R, SHI ED, PENG XX et al.: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect. Prev. (2005) 29:241-248.
12. HAMANAKA Y, SUEHIRO Y, FUKUI M et al.: Circulating anti-muc1 IGG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer (2002) 103:97-100.
13. NAKAMURA H, HINODA Y, NAKAGAWA N et al.: Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. (1998) 33:354-361. • In this paper, the authors evaluated the pathophysiological significance of circulating anti-MUC1 mucin core protein IgG antibodies (anti-MUC1 antibodies) in colorectal cancer.
14. REIPERT BM, TANNEBERGER S, PANNETA A et al.: Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol. Immunother. (2005) 54:1038-1042.
15. KONSTADOULAKIS MM, SYRIGOS KN, LEANDROS M et al.: Autoantibodies in the serum of patients with gastric cancer: their prognostic importance. Hybridoma (1998) 17:431-435.
16. WARD RL, HAWKINS NJ, COOMBER D et al.: Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum. Immunol. (1999) 60:510-515.
17. TAKAHASHI M, CHEN W, BYRD DR et al.: Antibody to ras proteins in patients with colon cancer. Clin. Cancer Res. (1995) 1:1071-1077. •• This manuscript describes a study with sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present.
18. WANG Y, WU XJ, ZHAO AL et al.: Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. (2004) 4:11-17.
19. SU Y, QIAN H, ZHANG J et al.: The diversity expression of p62 in digestive system cancers. Clin. Immunol. (2005) 116(2)118-123.
20. KASTAN MB, ONYEKWERE O, SIDRANSKY D et al.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. (1991) 51:6304-6311.
21. YONISH-ROUACH E, RESNITZKY D, LOTEM J et al.: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (1991) 352:345-347.
22. HAMMEL P, LEROY-VIARD K, CHAUMETE MT et al.: Correlations between p53-protein accumulation, serum antibodies and mutation in colorectal cancer. Int. J. Cancer (1999) 81:712-718.
23. POLGE A, BOURGAUX JF, BANCEL E et al.: p53 and follow-up of colorectal adenocarcinomas. Dig. Dis. Sci. (1998) 43:1434-1442.
24. FENOGLIO-PREISER CM, WANG J, STEMMERMANN GN et al.: p53 and gastric carcinoma: a review. Hum. Mutat. (2003) 21:258-370.
25. RYDER SD, RIZZI PM, VOLKMANN M et al.: Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J. Clin. Pathol. (1996) 49:295-299.
26. DAVIDOFF AM, IGLEHART JD, MARKS JR: Immune response to p53 is dependent upon p53/HS70 complexes in breast cancer. Proc. Natl. Acad. Sci. USA (1992) 89:3439-3442.
27. SOUSSI T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. (2000) 60:1777-1788.
28. FORSLUND A, KRESSNER U, LINDMARK G et al.: Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Int. J. Oncol. (2001) 19:501-506.
29. WINTER SF, MINNA JD, JOHNSON BE et al.: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. (1992) 52:4168-4174.
30. PARASHAR K, SOBTI RC: A study on protein p53 and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat. Res. (1998) 422:271-277.
31. BARNES DM, HANDY AM, GILLETT CE et al.: Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 340:259-263.
32. HALL PA, MCKEE PH, DU P et al.: High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 8:203-207.
33. BAAS IO, MULDER JW, OFFERHAUS JA et al.: An evaluation of six antibodies for immunohistochemistry of mutant p53 product in archival colorectal neoplasms. J. Pathol. (1994) 172:5-12.
34. BARNES DP, HANDLY AM, GILLET CE: Abnormal expression of wild type p53 protein in normal cell of cancer family patient. Lancet (1992) 340:259-263.
35. LANE DP, CRAWFORD LV: T antigen is bound to a host protein in SV40 transformed cells. Nature (1979) 278:261-263.
36. BENNETT WP, COLBY TV, TRAVIS WD et al.: P53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. (1993) 53:4817-4822.
37. PREUDHOMME C, LUBIN R, LEPELLEY P et al.: Detection of serum and p53 antibodies and their correlation with p53 mutations in myelodyplastics syndromes and acute myeloid leukemia. Leukemia (1994) 8:1589-1591.
38. SHIMADA H, OCHIAI T, NOMURA F: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer (2003) 97:682-689.
39. RAEDLE J, OREMEK G, WELKER M et al.: P53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas (1996) 13:241-246.
40. EDIS C, KAHLER C, KLOTZ W et al.: A comparison between a-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma. Transplant. Proc. (1998) 30:780-781.
41. SAFFROY R, LELONG JC, AZOULAY D et al.: Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br. J. Cancer (1999) 79:604-610.
42. NOMURA F: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer (2003) 97:682-689.
43. KOZLOWSKI M, KOVALCHUK O, NIKLINSKI J et al.: Circulating anti-p53 antibodies in esophageal cancer patients. Folia Histochem. Cytobiol. (2001) 39:173-174.
44. TANG R, KO MG, WANG JY et al.: Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer (2001) 94:85-863.
45. SHIMIZU K, UEDA Y, YAMAGISHI H: Titration of serum p53antobodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer (2005) 8:214-219.
46. SHIMADA H, OCHIAI T, BIELICKI D et al.: Clinicopathological charactetistics of colorectal cancer and serum anti-p53 antibodies. Pol. J. Pathol. (1999) 50:77-81.
47. TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur. J. Surg. (2001) 167:50-53.
48. SHIMADA H, OKAZUMI S, TAKEDA A et al.: Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg. Today (2001) 31:591-596.
49. HAGIWARA N, ONDA M, MIYASHITA M et al.: Detection of circulating anti-p 53 antibodies in esophageal cancer patients. J. Nippon Med. Sch. (2000) 67:110-117.
50. RALHAN R, ARORA S, KANT TC et al.: Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int. J. Cancer (2000) 85:791-795.
51. BERGSTROM S, DREILICH M, WAGENIUS G et al.: The presence of anti-p53 antibodies in sera from patients with esophageal carcinoma: correlation to treatment, tumor volume and survival. In Vivo (2004) 18:615-620.
52. NAKAJIMA K, SUZUKI T, SHIMADA H et al.: Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumor Biol. (1999) 20:147-152.
53. HOUBIERS JG, VAN DER BURG SH, VAN DE WATERING LM et al.: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer (1995) 72:637-664.
54. LECHPAMMER M, LUKAC J, LECHPAMMER S et al.: Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. (2004) 19:114-120.
55. SHIOTA G, ISHIDA M, NOGUCHI N et al.: Clinical significance of serum P53 antibody in patients with gastric cancer. Res. Commun. Mol. Pathol. Pharmacol. (1998) 99:41-51.
56. MAEHARA Y, KAKEJI Y, WATANABE A et al.: Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (1999) 85:302-308.
57. WURL P, WEIGMANN F, MEYE A et al.: Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand. J. Gastroenterol. (1997) 32:1147-1151.
58. SHIMADA H, NABEYA Y, OKAZUMI S et al.: Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery (2002) 132:41-47.
59. WANG MH, LI YP, WANG XD et al.: Correlation between serum p53 antibody and chemosensitivity in patients with esophageal cancer. Ai Zheng (2004) 23:467-470.
60. CARBONE D: Smoking habit and cancer. Am. J. Med. (1992) 93(Suppl. 1A):13S-17S.
61. TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int. J. Clin. Oncol. (2001) 6:45-49.
62. SHIBATA Y, KOTANAGI H, ANDOH H et al.: Detection of circulating and p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis. Colon Rectum (1996) 39:1269-1274.
63. SHIMADA H, NAKAJIMA K, OCHIAI T et al.: Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. Oncol. Rep. (1998) 5:871-874.
64. TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring. Gan To Karagu Ryoho (1999) 26:2189-2194.
65. TAKEDA A, AKIHIKO H, NAKAJIMA K et al.: Detection of serum p53 antibodies in mucosal colorectal cancer and negative conversion after endoscopic resection. J. Clin. Gastroenterol. (1999) 28:153-154.
66. VOLKMANN M, MULLER M, HOFMANN WJ et al.: The humoral immune response to p53 in patients with hepatocellular carcinoma in specific for malignancy and independent of the alpha-fetoprotein status. Hepatology (1993) 18:559-565.
67. RAEDLE J, ROTH WK, OREMEK G et al.: Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig. Dis. Sci. (1995) 40:2587-2594.
68. BENARD J, DOUC-RASY S, AHOMADEGBE JC: Tp53 family members and human cancers. Hum. Mutat. (2003) 21:182-191.
69. CIOFFI M, RIEGLER G, VIETRI MT et al.: Serum p53 antibodies in patients affected with ulcerative colitis. Inflamm. Bowel Dis. (2004) 10:606-611.
70. CAWLEY HM, MELTZER SJ, DE BENEDETTI VM et al.: Anti-p53 antibodies in patients with Barretts oesophagus or oesophageal carcinoma can predate cancer diagnosis. Gastrenterology (1998) 115:19-27.
71. LI Y, KARJALAINEN A, KOSKINEN H et al.: P53 autoantibodies predict subsequent development of cancer. Int. J. Cancer (2005) 114:157-160.
72. RAEDLE J, OREMEK G, ROTH WK et al.: Anti-p53 autoantibodies in hepatitis c virus-infected patients. Anticancer Res. (1997) 17:3079-3082.
73. TAKEDA A, NAKAJIMA K, SHIMADA H et al.: Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J. Surg. Oncol. (1999) 71:112-116.
74. MAETA M, SAITO H, OKA S et al.: Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer. J. Exp. Cancer Res. (2000) 19:489-495.
75. WU CW, LIN YY, CHEN GD et al.: Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br. J. Cancer (1999) 80:483-488.
76. BERGQVIST AS, BERGQVIST M, BRATTSTROM D et al.: Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res. (2001) 21:4141-4145.
77. VAN DER BURG SH, DE COCK K, MENON AG et al.: Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol. (2001) 31:146-155.
78. TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Clinical significance of serum p53 antibody detection in a chemosensitivity assay in case of human colorectal cancer. Gan To Kagaku Ryoho (2000) 27:876-888.
79. BEAUCHEMIN N, BENCHIMOL S, COURNOYER D et al.: Isolation and characterization of full length functional cDNA clones for human carcinoembryonic antigen. Mol. Cell. Biol. (1987) 7:3221-3230.
80. NIGHAM K, SAVAGE F, STAMP GW et al.: Loss of cell-cell and cell-matrix adhesion molecules in colorectal cancer. J. Cancer (1993) 68:507-513.
81. OIKAWA S, IMAJO S, NOGUCHI T et al.: The carcinoembryonic antigen contains multiple immunoglobulin-like domains. Biochem. Biophys. Res. Commun. (1987) 144:634-648.
82. STAAB HJ, ANDERER FA, STUMPF E et al.: Prognostic value of circulating immune complexes of carcinoembryonic antigen (CEA) in patients with adenocarcinoma of the gastrointestinal tract. J. Clin. Chem. Biochem. (1980) 18:175-181.
83. METERRISIAN S, FORD R, TOTH CA: Carcinoembryonic antigen is an adhesion molecule for colorectal carcinomas. Proc. Am. Assoc. Cancer Res. (1991) 32:72.
84. CLARK GW, IRELAND AP, HAGEN JA et al.: Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am. J. Surg. (1995) 170:597-600.
85. CASTALDI F, MARINO M, BENEDUCE L et al.: Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int. J. Biol. Markers (2005) 20:204-208.
86. STAAB HJ, ANDERER FA, BRUMENDOR FT et al.: Prognostic value of preoperative serum CEA level as a prognostic indicator in colorectal carcinoma. Br. J. Cancer (1981) 44:652-662.
87. CARRIQUIRY L, PINEYRO A: Should Carcinoembryonic antigen be used in the management of patients with colorectal cancer. Dis. Colon Rectum (1999) 42:921-929. • This paper describes a retrospective review of colorectal cancer patients in an attempt to get some valid answers to the function of CEA in the diagnosis, prognosis and overall management of colorectal cancer patients.
88. LAMERZ R: Role of tumor markers, cytogenetics. Ann. Oncol. (1999) 10:145-149.
89. OKADA M, NISHIO W, SAKAMOTO T et al.: Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann. Thorac. Surg. (2004) 78:1004-1009.
90. HERRERA MA, CHU TM, HOLYOKE ED: CEA is a prognostic and monitoring test in clinical complete resection of colorectal carcinoma. Ann. Surg. (1976) 183:5-9. • In this paper the authors compared the prognostic and postoperative monitoring capabilities of the CEA assay to pathological staging of the operative specimens, clinical follow-up including endoscopy, radiology and scanning techniques, as well as dinitrochlorobenzene skin testing and laboratory enzyme determinations (alkaline phosphatase and transaminase).
91. ZAMCHECK N: CEA in diagnosis, prognosis, detection of recurrence and evaluation of therapy of colorectal cancer. In: Clinical Application of CEA Assay. Krebs BP, Lalanne CM, Schneider M (Eds), Excerpta Medica, Amsterdam, The Netherlands (1978):64-79.
92. MAVLIGIT GM, STUCKEY S: Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer (1983) 52:146-149.
93. GOLD P: Circulating antibodies against carcinoembryonic antigens of the human digestive system. Cancer (1967) 20:1663-1667.
94. GOLD JM, BANJO C, FREEDMAN SO et al.: Immunochemical studies of the intramolecular heterogeneity of the carcinoembryonic antigen (CEA) of the human digestive system. J. Immunol. (1973) 111:1872-1879.
95. YCHOU M, PELEGRIN A, FAUROUS P et al.: Phase-I/II radio immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer. Int. J. Cancer (1998) 75:615-619.
96. CORNY RM, ALLEN KO, LEE S et al.: Human autoantibodies to carcinoembrionic (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. (2000) 6(1):34-41.
97. FRENOY N, SCHAUFFLER J, CAHOUR A et al.: Natural antibodies against carcinoembryonic antigen (CEA) and a related antigen, NCA, in human sera. Anticancer Res. (1987) 7:1229-1233.
98. BURTIN P: The carcinoembryonic antigen (CEA) of the digestive system and the antigens cross-reacting with it. Ann. Immunol. (1978) 129:185-198.
99. HOLBURN AM, MATCH JP, MACDONALD D et al.: Studies of the association of the A, B and Lewis blood group antigens with CEA. Immunology (1974) 26:831-843.
100. URA Y, OCHI Y, HAMAZU M et al.: Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients. Cancer Lett. (1985) 25:283-295.
101. SCHOENFIELD Y: Autoantibodies in the sera of cancer patients. Cancer (1991) 12:353-359.
102. PRESSMAN D, CHU TM, GROSSBERG AL: Carcinoembryonic antigen-binding immunoglobulin isolated from normal human serum by affinity chromatography. J. Natl. Cancer Inst. (1980) 12:195-197.
103. SYRIGOS KN, KARAYIANNAKIS AJ, ZBAR A: Mucins as immunogenic targets in cancer. Anticancer Res. (1999) 19(6B):5239-5244. •• In this paper the authors reviewed the structural differences between 'native' mucins and those detected on malignant cells, a knowledge of which would aid in the design of better antimucin vaccines for use in several carcinomas.
104. AJIOKA Y, WATANABE H, JASS JR: MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J. Clin. Pathol. (1997) 50:417-421.
105. GENDLER SJ, SPICER AP: Epithelial mucin genes. Anna. Rev. Physiol. (1995) 57:607-634.
106. LAPANSEE L, PANQUETTE Y, BLEAU G: Allelic polymorphism and chromosomal localization of the human oviductin gene (MUC9). Fertil. Steril. (1997) 68:702-708.
107. SHANKAR V, PICTAN P, EDDY JR et al.: Localization of human mucin gene (MUC8) and the cloning of the cDNA corresponding to the carboxy terminus. Am. J. Respir. Cell Mol. Biol. (1997) 16:232-241.
108. WILLIAMS SJ, MCGUCKIN MA, GOTLEY DC et al.: Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res. (1999) 59:4083-4089.
109. VON MENSDORFF-POUILLY S, SNIJDEWINT FG, VERSTRAETEN AA et al.: Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers (2000) 15(4):343-356.
110. CARRATO C, BALAGUE C, DE BOLOS C et al.: Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology (1994) 107(1):160-172.
111. VAN GONG N, AUBERT JP, GROSS MS et al.: Assignment of human tracheobronchial mucin gene(s) to 11p15 and a tracheobronchial mucin-related sequence to chromosome 13. Hum. Genet. (1990) 86:167-172.
112. BUISINE MP, DESSEYN JP, PORCHET N et al.: Genomic organization of the 3-region of the MUC5AC mucin gene: additional evidence for a common ancestral gene for the 11p15.5 mucin gene family. Biochem. J. (1998) 332:729-738.
113. KOCER B, SORAN A, ERDOGAN S et al.: Expression of MUC5AC in colorectal carcinoma and relationship with prognosis. Pathol. Int. (2002) 52:470.
114. YONEZAWA S, SATO E: Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol. Int. (1997) 47:813-830.
115. BALAQUE C, GAMBUS G, CARRATO C et al.: Altered expression of MUC2, MUC4 and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology (1994) 106:1054-1061.
116. TERADA T, OHTA T, SASAKI M et al.: Expression of MUC apomucin in normal pancreas and pancreatic tumors. J. Pathol. (1996) 180:160-165.
117. YONEZAWA S, HORINOUCHI M, OSAKO M et al.: Gene expression of gastric mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behaviour of the tumor. Pathol. Int. (1999) 49:45-54.
118. BALDUS SE, MONIQ SP, ARKENAU V et al.: Correlation of MUC5AC immunoreactivity with histopathological subtypes and prognosis of gastric carcinoma. Ann. Surg. Oncol. (2002) 9(9):887-893. •• In this paper the authors investigated MUC5AC reactivity by immunohistochemistry and correlated with prognosis.
119. NIWA T, IKEHARA Y, NAKANISHI H et al.: Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation. J. Histochem. Cytochem. (2005) 53(1):75-85.
120. GRINSTEAD JS, KOGARTY RR, KRANTZ MJ et al.: Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. Biochemistry (2002) 41(31):9946-9961.
121. KOTERA Y, FONTENOT JD, PECHER G et al.: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. (1994) 54:2856-2860.
122. KOCER B, MCKOLANIS J, SORAN A: Humoral immune response to MUC5AC in patients with colorectal carcinoma. BMC Gastroenterol. (2006) 6:4.
123. AMBROSINI S, ADIDA C, ALTIERI DC: A novel and apoptosis gene, surviving, expressed in cancer and lymphoma. Nat. Med. (1997) 3:917-921.
124. IKEGUCHI M, KAIBARA N: Survivin messenger RNA expression is a good prognostic biomarker for esophageal carcinoma. Br. J. Cancer (2002) 87:883-887. • The authors describe the prognostic significance of survivin mRNA expression in esophageal squamous cell carcinoma, analyzed quantitatively by real-time reverse transcriptase polymerase chain reaction.
125. MENG H, LU C, MABUCHI H, TANIGAWA N: Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett. (2004) 216(2):147-155.
126. MENG H, LU CD, SUN YL et al.: Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J. Gastroenterol. (2004) 10(22):3245-3250.
127. MENG H, LU D, DAI DJ et al.: Elevated expression level of wild-type survivin in gastric cancer promotes in vitro docetaxel-resistance. Zhonghua Yi Xue Za Zhi (2004) 84(24):2060- 2063.
128. JIANG ZM, YAO HR, ZHAN J et al.: Expression and significance of survivin in colon cancer. Ai Zheng (2004) 23(11 Suppl.):1414-1417.
129. CHEN WC, LIU Q, FU JX et al.: Expression of survivin and its significance in colorectal cancer. World J. Gastroenterol. (2004) 10(19):2886-2889.
130. KOBAYASHI Y, YUKIUE H, SASAKI H et al.: Developmentally regulated expression of survivin in the human thymus. Hum. Immunol. (2002) 63:101-107.
131. TAMM I, WANG Y, SAUSVILLE E et al.: IAP family protein survivin inhibits caspace activity and apoptosis induced by FAS(CD95) Bax, caspaces, and anticancer drugs. Cancer Res. (1998) 58:6315-6320.
132. MILLER LK: An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. (1999) 9:323-328.
133. ALTIERI DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. (2001) 7:542-547.
134. REED JC, BISCHOFF JR: Ringing chromosomes through cell division: and survivin' the experience. Cell (2000) 102:545-548.
135. GIODINI A, KALLIO MJ, WALL NR et al.: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. (2002) 62:2462-2467.
136. IKEGUCHI M, LIU J, KAIBARA N: Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis (2002) 7:23-29.
137. PAPAPETROPOULOS A, FULTON D, MAHBOUBI K et al.: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/surviving pathway. J. Biol. Chem. (2000) 275:9102-9105.
138. ROHAYEM J, DIESTELKOETTER P, WEIGLE B et al.: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. (2000) 60:1815-1817.
139. YAGIHASHI A, ASAMMA K, NAKAMURA M et al.: Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin. Chem. (2001) 9:47:1729-1731.
140. KASOF GM, GOMES BC: Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem. (2001) 276:3238-3246. •• This paper describes a novel human inhibitor of apoptosis protein family member termed livin.
141. VUCIC D, STENNICKE HR, PISABARRO MT et al.: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. (2000) 10:1359-1366.
142. LIN JH, DENG G, HUANG Q et al.: KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem. Biophys. Res. Commun. (2000) 279:820-831.
143. MOLLER P, KORETZ K, LEITHAUSER F et al.: Expression of APO-1(CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer (1994) 57(3):371-377.
144. HALL PA, COATES PJ, ANSARI B et al.: Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J. Cell Sci. (1994) 107:3569-3577.
145. BENNETT MW, O'CONNELL J, O'SULLIVAN GC et al.: Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. Dis. Esophagus (1999) 12:90-98.
146. OWEN-SHAUB LB, ZHANG W, CUSACK JC et al.: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. (1995) 15:3032-3040.
147. WYLLIE AH, BELLAMY CO, BUBB VJ et al.: Apoptosis and carcinogenesis. Br. J. Cancer (199S) 80(Suppl. 1):34-37.
148. BENNETT MW, O'CONNELL J, HOUSTON A et al.: Fas ligand upregulation is an early event in colonic carcinogenesis. J. Clin. Pathol. (2001) 54:598-604.
149. O'CONNELL J, BENNETT MW, O'SULLIVAN GC et al.: Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. (1998) 186:240-246. •• In this paper the authors present a study to ascertain the prevalence of FasL expression in human colon cancer and to confirm that neoplastic colonic epithelial cells express FasL in vivo.
150. SUZUKI A, ENARI M, EGUSHI Y et al.: Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J. (1996) 133:335-343.
151. LEE J, RICHBURG JH, YOUNKIN SC et al.: The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology (1997) 138:2081-2088.
152. ADACHI M, SUEMATSU S, KONDO T et al.: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. (1995) 11:294-300.
153. RESTIFO NP: Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. (2000) 6:493-495.
154. ALTZANAUER F, VON GUNTEN S, SPATH P et al.: Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. Allergy Clin. Immunol. (2003) 112:1185-1190.
155. STELLAMOR MT, REIPERT BM, POELL M et al.: Biological activity of antibodies against members of the TNF receptor superfamily that are present in normal human IgG. FASEB J. (2002) 16:A1247.
156. VIARD I, WEHRLI P, BULLANI R et al.: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 1282:490-493.
157. PRASAD NK, PAPOFF G, ZEUNER A et al.: Therapeutic preparations of normal polyspecific IgG (IVIG) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action IVIG involving the Fas apoptotic pathway. J. Immunol. (1998) 161:3781-3790.
158. YADIN O, SAROV B, NAGGAN L: Natural antibodies in serum of healthy women. A five year follow up. Clin. Exp. Immunol. (1989) 75:402-405.
159. NJEMINI R, MEYERS I, DEMANET C: The prevalence of auto-antibodies in an elderly sub-Saharan African population. Clin. Exp. Immunol. (2002) 127:99-106.
160. BOOTSMA H, SPRONK PE, HUMMEL EJ et al.: Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand. J. Rheumatol. (1996) 25:352-359.
161. SOLANS-LAQUÉ R, PÉREZ-BOCANEGRA C, SALUD-SALVIA A et al.: Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus (2004) 13(3):159-164. • In this paper the authors describe a study with an aim to determine the prevalence of ANA in patients with malignancies and to investigate if their presence might be related with development of musculoskeletal symptoms or paraneoplastic rheumatic syndromes.
162. SYRIGOS KN, CHARALAMBOPOULOS A, PLIARCHOPOULOU K et al.: The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. (2000) 20:4351-4354.
163. IMAI H, NAKANO Y, OCHS RH et al.: Nuclear antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am. J. Pathol. (1992) 140:859-870.
164. IMAI H, NAKANO Y, KIYOSAWA K et al.: Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer (1993) 71:26-35.
165. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
166. SHUN LV, ZHANG J, JIN WU et al.: Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol. Lett. (2005) 99:217-227.
167. MOY PM, HOLMES EC, GOLUB SH: Depression of natural killer cell cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. (1985) 45:57-60.
168. LE LANN AD, FOURNIE GJ, BOISSIER L, TOUTAIN PL, BENOIST H: In vitro inhibition of natural-killer-mediated lysis by chromatin fragments. Cancer Immunol. Immunother. (1994) 39:185-192.
169. BELL DA, MORRISON B: The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. (1991) 60:13-26.
170. KOZYR AV, SASHCHENKO LP, KOLESNIKOV AV et al.: Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett. (2002) 80:41-47.
171. ALARCON-SEGOVIA D, RUIZ-ARGUELLES A, LLORENTE L: Broken dogma: penetration of autoantibodies into living cells. Immunol. Today (1996) 17:163-164.
172. RUIZ-ARGUELLES A, PEREZ-ROMANO B, ALARCON-SEGOVIA D et al.: Penetration of anti-DNA antibodies into immature live cells. J. Autoimmun. (1998) 11:547-556.
173. SHUSTER AM, GOLOLOBOV GV, KVASHUK OA et al.: DNA hydrolyzing autoantibodies. Science (1992) 256:665-667.
174. DUBROVSKAYA VV, ANDRYUSHKOVA AS, KUZNETSOVA IA et al.: DNA hydrolyzing autoantibodies from sera of autoimmune-prone MRL/MpJ-Ipr mice. Biochemistry (2003) 68:1081-1088.
175. SCANLAN MJ, SIMPSON AJ, OLD LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. (2004) 4:1-14.
176. CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94:1914-1918.
177. FUGITA S, WADA H, JUNGBLUTH AA et al.: NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin. Cancer Res. (2004) 10:6551-6558.
178. LI M, YUAN YH, HAN Y et al.: Expression profile of cancer-testis genes in 121 humoral colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. (2005) 11:1809-1814.
179. WANG Y, WU XJ, ZHAO AL et al.: Cancer-testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. (2004) 4:11.
180. AKCAKANAT A, KANDA T, KOYAMA Y et al.: NY-ESO-1 expression and its serum mmunoreactivity in esophageal cancer. Cancer Chemother. Pharmacol. (2004) 54:95-100.
181. WU XJ, WANG Y, JI JF: Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma. Beijing Da Xue Xue Bao (2005) 37(3):252-256.
182. SCANLAN MJ, WELT S, GORDON CM et al.: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. (2002) 62:4041-4047.
183. WALDE A, KUBUSCHOK B, IMIG J et al.: Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int. J. Cancer (2006) 119(1):117-125.
184. STOCKERT E, JAGER E, CHEN YT et al.: A survey of the humoral immune response of cancer patients to a panel of human tumors antigens. J. Exp. Med. (1998) 187:1349-1354.
185. BALZAR M, WINTER MJ, DE BOER CJ et al.: The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. (1999) 77:699.
186. SHETYE J, CHRISTENSSON B, RUBIO C et al.: The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res. (1989) 9:395.
187. MOSOLITIS S, HARMENBERG U, RUDEN U et al.: Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother. (1999) 47(6):315-320.
188. SYRIGOS KN, CHARALAMPOPOULOS A, PLIARCHOPOULOU K et al.: Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Hybridoma (1999) 18(6):543-546.
189. SYRIGOS KN, CHARALAMPOPOULOS A, KONSTANTOULAKIS MM, KARAYIANNAKIS A, TSIBLOULIS V, PEVERETOS P: Autoantibodies against cardiolipin in the serum of patients with colorectal adenocarcinoma: their prognostic significance. Eur. Surg. Res. (1998) 30(1):55-60.
190. SYRIGOS KN, KONSTANTOULAKIS MM, FYSSAS I, KATSILAMBROS N, GOLEMATIS BC: Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus. Int. J. Cancer. (1996) 66(5):624-626.
191. FYSSAS I, SYRIGOS KN, KONSTANTOULAKIS MM et al.: Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncol. (1997) 36(1):65-68.
192. SYRIGOS KN, KONSTANTOULAKIS MM, CONSTANTOULAKIS M, MARAFELIA P, KOUTRAS D, GOLEMATIS BC: Thyroid autoantibodies and thyroid function in patients with gastric cancer. Acta Oncol. (1994) 33(8):905-907.
193. SCANLAN MJ, WELT S, GORDON CM et al.: Cancer-related serological recognition of human colon cancer: identification of potential and immunotherapeutic targets. Cancer Res. (2002) 62:4041-4047.
194. SOMERS VA, BRANDWIJK RJ, JOONSTEN B et al.: A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J. Immunol. (2002) 169:2772-2780.
195. ANDERSON KS, LABAER J: The sentinel within: exploiting the immune system for cancer biomarkers. J. Proteome Res. (2005) 4:1123-1133.
196. FLAMINI G, CURIGLIANO G, RATTO C et al.: Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur. J. Cancer (1996) 32A:802-806.
197. KOZIOL JA, ZHANG JY, CASIANO CA et al.: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. (2003) 9:5120-5126.
198. SYRIGOS KN, KARAPANAGIOTOU E, HARRINGTON KJ: The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics (2004) 23(6):335-342.
199. SYRIGOS KN, PLIARCHOPOULOU K, HARRINGTON KJ: The development of monoclonal antibody therapy in leukemias. Hybridoma (2001) 20(3):145-148.
200. ZBAR AP, THOMAS H, WILKINSON RW et al.: Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a Phase I study. Int. J. Colorectal Dis. (2005) 20(5):403-414.
201. SYRIGOS KN, DEONARIAN DP, EPENETOS AA: Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. Hybridoma (1999) 18(3):219-224.
202. SYRIGOS KN, DEONARAIN DM, KARAYIANNAKIS A, WAXMAN J, KRAUSZ T, PIGNATELLI M: Epithelial mucin expression in bladder cancer: correlation with pathological and clinical parameters. Urol. Res. (2000) 28(4):241-245.
203. SYRIGOS KN, EPENETOS AA: Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res. (1999) 19(1A):605-613.